| 1 | OncoIndx® Prime + Comprehensive Multi-omics-based Tissue-Liquid Normal Match Test | A 360° Molecular Profiling Test combining DNA, RNA, Tissue-Liquid-Normal Match Testing including IHC based Protein markers analysing tumor and normal samples from the same patient simultaneously. 5 layered Multi-omics test with Tissue-Liquid-Normal Matched Molecular Profiling-a. Genomics on Tissue Biopsy b. Transcriptomics on Tissue Biopsy c. Proteomics (IHC based) on Tissue biopsy d. Genomics on Liquid Biopsy e. Genomic DNA for normal match-identifying true somatic and true germline variants Tumor-liquid - normal match test for the identification of true somatic and true germline variants for enhanced detection rate, higher sensitivity of MSI, TMB & HRD and copy number variations with accurate identification of reversal and CHIP variants Genomics: 1080 genes analysed on tissue biopsy and ctDNA for SNVs, Indels, CNVs and 50 fusions (covering 138 fusion partners), > 50 HRR genes, 350 genes for resistance to therapy, Genome wide LOH markers (16,000 markers), MSI on NGS (2000 microsatellite hotspots and MMR genes), TMB estimation, HRD score (based upon LOH, TAI and LST), 36 pharmacogenomic markers for response to chemotherapy Longitudinal Monitoring: using ctDNA load serving as the basal level of the biomarker to track treatment response/ longitudinal monitoring subsequently. CTC test can be provided as an additional biomarker (upon request) Transcriptomics: Whole transcriptome sequencing covering 25,000 genes for detection of RNA based fusions (known and novel), RNA expressed variants and gene expression analysis IHC based Proteomics: Protein expression using IHC based diagnostic and predictive biomarkers Sequencing Depth: 2000X (tissue biopsy) and 10,000X (liquid biopsy) | FFPE tissue + plasma cfDNA (BD PaxGene Tube) + 10 mL blood in K2EDTA tube | 17-20 Working Days | 45 890 000 |
| 2 | OncoIndx® TBx (Tissue biopsy) Advanced Comprehensive Genomic Profiling | 1080 genes analysed on tissue biopsy for SNVs, Indels, CNVs and 50 fusions (covering 138 fusion partners), > 50 HRR genes, 350 genes for resistance to therapy, Genome wide LOH markers (16,000 markers), MSI on NGS (2000 microsatellite hotspots and MMR genes), TMB estimation, HRD score (based upon LOH, TAI and LST), 36 pharmacogenomic markers for response to chemotherapy, PDL1 expression on IHC (tested for cancers based upon guidelines) Longitudinal Monitoring: Longitudinal Monitoring using CTC can be done as an add-on test (upon request). Sequencing Depth: 2000X (tissue biopsy) | FFPE tissue | 12-14 Working Days | 29 700 000 |
| 3 | OncoIndx® TBx & Transcriptomic Profiling (Tissue biopsy) Advanced Comprehensive Genomic Profiling | OncoIndx Tbx covers an integrated DNA and RNA based sequencing to provide a complete molecular picture of the tumor. *It covers 1080 genes analysed on tissue biopsy for SNVs, Indels, CNVs, and 50 fusions (covering 138 fusion partners), > 50 HRR genes, 350 genes for resistance to therapy, Genome wide LOH markers (16,000 markers), MSI on NGS (2000 microsatellite hotspots and MMR genes), TMB estimation, HRD score (based upon LOH, TAI and LST), 36 pharmacogenomic markers for response to chemotherapy on DNA*. It also covers *Whole Transcriptome Sequencing based for known, rare and novel fusions on RNA*. Additionally, it covers *PDL1 expression on IHC* (tested for cancers based upon guidelines) Longitudinal Monitoring: Longitudinal Monitoring using *CTC can be done as an add-on test* (upon request). Sequencing Depth: 2000X (tissue biopsy) | FFPE tissue | 12-14 Working Days | 36 300 000 |
| 4 | OncoIndx® LBx (Liquid biopsy) Advanced Comprehensive Genomic Profiling | 1080 genes analysed on liquid biopsy (ctDNA) for SNVs, Indels, CNVs and 50 fusions (covering 138 fusion partners), > 50 HRR genes, 350 genes for resistance to therapy, Genome wide LOH markers (16,000 markers), MSI on NGS (2000 microsatellite hotspots and MMR genes), TMB estimation, HRD score (based upon LOH, TAI and LST), 36 pharmacogenomic markers for response to chemotherapy Longitudinal Monitoring: Longitudinal Monitoring using ctDNA load serving as the basal level of the biomarker to track treatment response/ longitudinal monitoring subsequently CTC test can be provided as an additional biomarker (upon request) Sequencing Depth: 10,000X (liquid biopsy) | 15-20 mL liquid biopsy sample (2 x BD PaxGene Tube/ Streck tube) | 12-14 Working Days | 34 300 000 |
| 5 | OncoMonitor® MRD (Liquid biopsy) For MRD Detection | Dual biomarker analysis for cancer longitudinal monitoring, treatment efficacy a. ctDNA load estimation and based on methylation b. CTC enumeration Sequencing Depth: 10,000X (liquid biopsy) | 15-20mL liquid biopsy sample (2 x BD PaxGene Tube/ Streck tube) + 1 Tube of 10 ml Peripheral Whole Blood in K2EDTA Tube | 12-14 Working Days | 12 636 000 |
| 6 | OncoMonitor® TRM (Liquid biopsy) Liquid Biopsy Test for Longitudinal Cancer Monitoring | Dual biomarker analysis for cancer longitudinal monitoring, treatment efficacy a. ctDNA load estimation and based on methylation b. CTC enumeration c. Pertinent mutations on ctDNA (100+ gene NGS panel with complete gene sequencing for SNVs, Indels, CNVs and certain Fusions, MSI by NGS for understanding tumor heterogeneity and clinical insights for targeted therapies) Sequencing Depth: 10,000X (liquid biopsy) | 15-20mL liquid biopsy sample (2 x BD PaxGene Tube/ Streck tube) + 1 Tube of 10 ml Peripheral Whole Blood in K2EDTA Tube | 12-14 Working Days | 14 300 000 |
| 7 | OncoTarget® TBx (Tissue biopsy) Tailored NGS Panel for Solid Tumors | 100+ gene panel, complete gene sequencing on tissue biopsy for SNVs, Indels, CNVs and specific Fusions; MSI on NGS, Pharmacogenomics of DPYD gene (for drug response, adverse events and toxicity), covers genes for treatment resistance Sequencing Depth: 2000X (tissue biopsy) | FFPE tissue | 12-14 Working Days | 9 172 000 |
| 8 | OncoTarget® TBx + PDL-1 (Ventana) (Tissue biopsy) Tailored NGS Panel for Solid Tumors | 100+ gene panel, complete gene sequencing on tissue biopsy for SNVs, Indels, CNVs and specific Fusions; MSI on NGS, Pharmacogenomics of DPYD gene (for drug response, adverse events and toxicity), covers genes for treatment resistance, PDL-1 on IHC (Ventana SP263 clone) Sequencing Depth: 2000X (tissue biopsy) | FFPE Tissue | 12-14 Working Days | 10 395 000 |
| 9 | OncoTarget® TBx + PDL-1 (Dako 22C3) (Tissue biopsy) Tailored NGS Panel for Solid Tumors | 100+ gene panel, complete gene sequencing on tissue biopsy for SNVs, Indels, CNVs and specific Fusions; MSI on NGS, Pharmacogenomics of DPYD gene (for drug response, adverse events and toxicity), covers genes for treatment resistance, PDL-1 on IHC (Dako 22C3 clone) Sequencing Depth: 2000X (tissue biopsy) | FFPE tissue | 12-14 days | 12 230 000 |
| 10 | OncoTarget® LBx (Liquid biopsy) Tailored NGS Panel for Solid Tumors | 100+ gene panel, complete gene sequencing on liquid biopsy (ctDNA) for SNVs, Indels, CNVs and specific Fusions; MSI on NGS, Pharmacogenomics of DPYD gene (for drug response, adverse events and toxicity), covers genes for treatment resistance Sequencing Depth: 10,000X (liquid biopsy) | Plasma cfDNA (BD PaxGene Tube) | 12-14 days | 11 211 000 |
| 11 | OncoHRD® (Tissue biopsy) A Next Generation Assistive HRD Test | Analyses 50+ HRR genes detecting SNVs, Indels, CNVs and large structural variations, provides HRD scoring based upon LOH, LST and TAI for precise tumor profiling, supporting PARP inhibitors and platinum based therapies recommendation for improved outcomes Sequencing Depth: 2000X (tissue biopsy) | FFPE tissue | 12-14 days | 16 307 000 |
| 12 | OncoRisk® (Germline Test) Hereditary and Familial Cancer Risk Test | Comprehensive germline panel of NCCN recommended 74 genes associated with a spectrum of more than 11 hereditary and familial cancers. Genomic alterations covered include SNVs and CNVs in the 74 genes on genomic DNA. Test reports cancer risk based upon germline variant findings. Helps identify potential risks early, enabling timely interventions and personalised care. | 5 mL blood in K2EDTA tube | 12-14 days | 6 115 000 |
